Evaluation of the Osteoregenerative potential of anti resorptive agents in mg63 cell line with a high glucose environment simulating diabetes for enhancing implant Osseointegration An in vitro study

Abstract

Systemic factors like diabetes mellitus with hyperglycemia inhibit osteoblastic differentiation and alter the parathyroid hormone response that regulates phosphorus and calcium metabolism essential for bone mineralization and remodeling We aimed to investigate the effects of alendronate and simvastatin drugs for invitro evaluation on the proliferation and osteogenic potential in a hyperglycemic situation The evaluation of the osteogenic proliferation and differentiation of alendronate and simvastatin in the MG63 cell line induced in a hyperglycemic situation was done by using alkaline phosphatase assay acridine orange propidium iodide assay analysis of gene expression by real time quantitative polymerase chain reaction and alizarin red staining assay Statistical analysis included ANOVA The alkaline phosphatase activity in the 3and#956;M treated simvastatin and alendronate treated groups increased above the controls induced in a hyperglycemic situation Further at 3and#956;M concentration showed an increase in live cells in hyperglycemic conditions when performing the AO/PI assay There was upregulation of osteocalcin and bone morphogenic protein 2 genes by real time quantitative polymerase chain reaction assay in the 3and#956;M treated group of the anti resorptive drugs There was also an increase in calcium deposition by evaluating the alizarin red staining assay The results of the current study in MG63 cells stimulated with hyperglycemia exhibit positive osteogenic proliferation and differentiation when exposed to alendronate and simvastatin at a concentration of 3and#956;M The results demonstrated the beneficial effects of alendronate and simvastatin suggesting their potential for osteoregenerative implant therapy in hyperglycemic conditions newline